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ABSTRACT
Introduction Bronchiectasis is a multidimensional
disease associated with substantial morbidity and
mortality. Two disease-specific clinical prediction tools
have been developed, the Bronchiectasis Severity Index
(BSI) and the FACED score, both of which stratify
patients into severity risk categories to predict the
probability of mortality.
Methods We aimed to compare the predictive utility
of BSI and FACED in assessing clinically relevant disease
outcomes across seven European cohorts independent
of their original validation studies.
Results The combined cohorts totalled 1612. Pooled
analysis showed that both scores had a good
discriminatory predictive value for mortality (pooled area
under the curve (AUC) 0.76, 95% CI 0.74 to 0.78 for
both scores) with the BSI demonstrating a higher
sensitivity (65% vs 28%) but lower specificity (70% vs
93%) compared with the FACED score. Calibration
analysis suggested that the BSI performed consistently
well across all cohorts, while FACED consistently
overestimated mortality in ‘severe’ patients (pooled OR
0.33 (0.23 to 0.48), p<0.0001). The BSI accurately
predicted hospitalisations (pooled AUC 0.82, 95% CI
0.78 to 0.84), exacerbations, quality of life (QoL) and
respiratory symptoms across all risk categories. FACED
had poor discrimination for hospital admissions (pooled
AUC 0.65, 95% CI 0.63 to 0.67) with low sensitivity at
16% and did not consistently predict future risk of
exacerbations, QoL or respiratory symptoms. No
association was observed with FACED and 6 min walk
distance (6MWD) or lung function decline.
Conclusion The BSI accurately predicts mortality,
hospital admissions, exacerbations, QoL, respiratory
symptoms, 6MWD and lung function decline in
bronchiectasis, providing a clinically relevant evaluation
of disease severity.
INTRODUCTION
Bronchiectasis is a heterogeneous, poorly under-
stood, multidimensional disease with recent UK
and German data demonstrating increasing preva-
lence and hospitalisation rates.1–3 Management is
challenging as there are no licensed therapies.
Given that the majority of available treatments are
antibiotic-based, it is important for antimicrobial
stewardship to target treatments to patients at
severe risk of complications and avoid over-
treatment of mild patients at low future risk.4–6
Two composite disease-specific prognostic indices
have been developed for bronchiectasis to aid clin-
ical decision-making: the Bronchiectasis Severity
Index (BSI) and the FACED score.7 8 Both attribute
points according to age, value of FEV1 % pre-
dicted, presence of chronic colonisation by
Pseudomonas aeruginosa, radiological extension
and type of bronchiectasis and degree of dyspnoea.
The BSI also considers body mass index, exacerba-
tion frequency, prior hospitalisation for severe
exacerbation and chronic colonisation with bacteria
other than P. aeruginosa. Both scores classify
patients into low, moderate and high risk groups,
using different thresholds. The BSI was derived
Key messages
What is the key question?
What is the comparative predictive ability and
clinical utility of the two recently developed
disease-specific severity tools in bronchiectasis—
the Bronchiectasis Severity Index (BSI) and the
FACED score—in assessing clinically relevant
disease outcomes?
What is the bottom line?
This study of 1612 patients across seven European
cohorts shows that both tools accurately predict
mortality in bronchiectasis, but that the BSI is
superior to FACED in predicting multiple clinically
useful outcomes including hospital admissions,
exacerbations, quality of life, respiratory symptoms,
exercise capacity and lung function decline.
Why read on?
This study demonstrates that the BSI provides an
accurate assessment of disease severity enabling
‘real-world’ decision-making in terms of identifying
high-risk patients who may benefit from aggressive
treatment and low-risk patients who could receive
non-specialist follow-up or simpler treatment
regimes.
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from a large Edinburgh-based study in the UK and was subse-
quently validated in four international cohorts.7 The FACED
score was derived from a retrospective Spanish study and was
recently independently evaluated in a single centre UK cohort
of 74 patients for long-term prediction of mortality.8 9 FACED
was developed specifically to predict mortality, while the BSI
was developed to predict mortality, severe exacerbations, fre-
quency of exacerbations and quality of life (QoL).
The data currently available suggest that both scores can predict
future mortality in bronchiectasis. Bronchiectasis is not, however,
a disease whose impact is primarily measured in terms of mortality.
Outcomes other than mortality are likely to be more important in
terms of patients priorities, clinical decision-making, healthcare
utilisation and socioeconomic costs.2 3 Clinicians face two major
challenges in the management of bronchiectasis: (1) identifying
patients with a high symptom burden or those at risk of frequent
exacerbations or rapid lung function decline who may benefit
from aggressive treatment and (2) identifying low-risk patients
who could be suitable for non-specialist follow-up or simpler treat-
ment regimes. No therapy has been developed that can reduce
mortality in bronchiectasis, but existing and developing therapies
are designed to improve QoL, reduce symptoms, reduce exacerba-
tions and slow disease progression.4–6 10–13 Therefore for clinical
trial design and subsequent ‘real world’ decision-making, these are
the key outcomes to identify.13 The concept of ‘severe’ bronchiec-
tasis should therefore reflect patients with impaired QoL, severe
symptoms, frequent exacerbations and progressive disease.
There are limited published data on predictors of outcomes
other than mortality in bronchiectasis. This study aimed to
evaluate the predictive ability of the two bronchiectasis tools,
the BSI and FACED score, in assessing clinically relevant disease
outcomes across seven European cohorts.
METHODS
Study population
Seven European centres participating in the European
Bronchiectasis registry project contributed to the study. Detailed
descriptions of these cohorts have previously been published.7 14–19
All cohorts used a standardised protocol and provided data in a
standardised case report form. Inclusion criteria were consecutive
adult patients with a high resolution CT-confirmed diagnosis and
clinical history consistent with bronchiectasis. Patients were
excluded if they had active malignancy, cystic fibrosis or a primary
diagnosis of pulmonary fibrosis/sarcoidosis with secondary traction
bronchiectasis. Patients were assessed and managed according to a
standardised protocol based on the British Thoracic Society (BTS)
guidelines.13 Ethical approval was obtained from each individual
centre’s Research Ethics Committee. In order to ensure statistical
independence, the derivation cohorts of the BSI and FACED scores
were not considered for inclusion in the present analysis.7 8
Clinical assessments and calculation of severity scores
Patients were followed up at outpatient clinic assessments. The
underlying aetiology of bronchiectasis was determined following
testing recommended by BTS guidelines.13 The BSI and FACED
scores were calculated using baseline data as described.7 8
Patients were classified according to severity cut-offs described
in original publications as mild, moderate or severe.
Study end points
Mortality
Data on all-cause mortality were collected for up to 5 years in
keeping with follow-up periods of the original BSI and FACED
derivation cohorts.
Exacerbations
An exacerbation was defined as the requirement for antibiotics
in the presence of one or more symptoms of increasing cough,
increasing sputum volume, worsening sputum purulence, wor-
sening dyspnoea, increased fatigue/malaise, fever and haemopty-
sis.13 14 Exacerbations were recorded for 12 months after
severity score calculation.
Hospitalisation for severe exacerbations
Severe exacerbations were defined according to BTS guidelines
as unscheduled hospitalisations or emergency department visits
for exacerbations or complications as recorded from patient his-
tories and verified using administrative databases.13 Hospital
admissions were recorded up to 5 years follow-up post-score
calculation.
FEV1% predicted decline
This was analysed for up to 4 years of follow-up.
QoL
This was assessed by the QoL Bronchiectasis (QoL-B)
Questionnaire (V.3.1) and the St Georges Respiratory
Questionnaire (SGRQ), with minimum clinically important dif-
ferences (MCIDs) of 8 and 4 points, respectively.20 21
Symptoms and function
Cough symptoms were evaluated using the Leicester Cough
Questionnaire (LCQ) (MCID of 1.3 units).22 Exercise capacity
was evaluated with the 6 min walking distance (6MWD) test
which has an MCID of 84 m.23
Definition of validity
The validity of each scoring system was evaluated in terms of
discrimination- the degree to which groups are different from
each other, and calibration, the degree to which the scores
perform as expected across different healthcare systems. Good
discrimination and calibration are required for a score to be con-
sidered valid.
For mortality and hospitalisations, a scoring system was con-
sidered to be valid if the area under the receiver operator char-
acteristic curve (AUC) exceeded 0.7. A value of >0.7 is
generally regarded as clinically useful and was therefore chosen
as a cut-off for valid prediction.7 8 AUC evaluates discrimin-
ation. As mortality was the end point in both the BSI and
FACED derivation studies, we also evaluated calibration com-
pared with the original derivation. Scores were considered valid
if there was no statistically significant difference between pooled
event rates in the validation cohorts and the original predicted
event rate.24 For QoL and symptom scores, scores were consid-
ered to be valid if the differences between the three groups
exceeded the reported MCIDs.20–23
Statistical analysis
Simple descriptive statistics were used to compare baseline data
according to data distribution. Mean differences were compared
using t-test (or analysis of variance (ANOVA) for more than two
groups) and medians using the Mann-Whitney U test or
Kruskal-Wallis test as appropriate. The AUC was used for dis-
crimination analysis and differences between AUC values were
compared using the method of DeLong et al.25 For calibration
analysis, ORs and 95% CIs were calculated comparing event
rates in the validation cohorts with the original derivation
cohorts. Exacerbations and hospital admissions during
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follow-up were evaluated by Poisson regression analysis with
data presented as rate ratio (RR) with 95% CI.
Effect estimates were pooled using a random effects
meta-analysis to determine overall discrimination and calibra-
tion. Statistical heterogeneity between cohorts was assessed
using the Higgins I2 test.
Analyses were conducted using SPSS (V.21) for Windows
(SPSS, Chicago, Illinois, USA), Graph Pad Prism V.6 (Graph Pad
Software, San Diego, California, USA) and Metadisc (V.1.4;
Hospital Universitario Ramon y Cajal, Spain).
RESULTS
Baseline characteristics
Seven international cohorts were included comprising 1612
patients. The characteristics of each cohort are shown in table 1.
Cohorts were heterogeneous in keeping with the fact that they
were derived from different healthcare systems. However, all
cohorts had a female predominance. The average annual rate of
exacerbations ranged from 1 to 3/year. The cohorts were pri-
marily classified as moderate-to-severe bronchiectasis based on
mean BSI scores (6.0–9.7); however, in contrast, the majority
were considered to be mild bronchiectasis according to the
FACED score (mean 1.5–2.3). Data for mortality, hospitalisa-
tions and exacerbations were available in all seven cohorts.
Additional data were available for lung function decline, 6 min
walk test, QoL and LCQ from two cohorts (Dundee and
Monza) comprising 744 patients.
Mortality
Outcomes across each of the cohorts are shown in table 2.
There was a clear difference in classification of the scores, with
the BSI identifying 16.7%–38.9% of patients as low risk versus
52.6%–72% with FACED. A much larger number of patients
were identified as having severe bronchiectasis with the BSI,
21.2%–63.5%, compared with 3.6%–13.2% with FACED.
There were no deaths in the low-risk BSI group in the
Newcastle, Monza, Athens and Vojvodina cohorts and there
were only 11 deaths in the low-risk groups overall (2.4%), com-
pared with 57 deaths in the ‘mild’ bronchiectasis group accord-
ing to FACED (5.6%). Mortality rates were higher for patients
classed as severe using FACED (35.1%) compared with the BSI
(21.6%) (shown in table 2).
The scores had very different characteristics in identifying
patients at high risk of death. The FACED score had poor sensi-
tivity ranging from 5% to 56% with a pooled sensitivity from
meta-analysis across all seven cohorts of 28% (22%–36%). In
contrast, the BSI was more sensitive (ranging from 40% to
100%, pooled value 65% (57%–71%) but less specific (range
41%–83%, pooled value 70% (66%–72%)) compared with
FACED 93% (92%–95%).
Comparing AUC scores for mortality, the BSI had a numeric-
ally higher AUC in the Dundee, Galway, Monza, Athens,
Newcastle and Vojvodina cohorts; the FACED score had a
numerically higher AUC in Leuven. The only statistically signifi-
cant difference was a superior AUC for the BSI in the Newcastle
cohort. All AUC values for BSI were above 0.7 and six AUC
values were above 0.7 for FACED, suggesting that both scores
are valid in terms of discrimination for mortality (table 3).
In the calibration analysis, both scores were well calibrated in
terms of identifying patients at low risk of death. For identify-
ing severe patients, however, the FACED score failed calibra-
tion with a pooled OR of 0.33 (0.23 to 0.48, p<0.0001),
suggesting that the true mortality rate is 70% lower than that
predicted by FACED. A meta-analysis of all available data for
mortality, including one previously published validation study
by Ellis et al,9 is shown in the online supplementary table S5(a)
and (b).
Hospital admissions
The BSI appeared to be superior to FACED in terms of predict-
ing hospital admissions. Rates of hospitalisation in mild patients
Table 1 Characteristics of included cohorts
Characteristics
Dundee,
Scotland
Galway,
Ireland Monza, Italy
Leuven,
Belgium
Athens,
Greece
Newcastle,
England
Vojvodina,
Serbia
N 494 280 250 190 159 126 113
Study dates 2011–2015 2008–2015 2011–2015 2006–2012 2010–2015 2009–2013 2010–2015
Age, mean (SD) 65.3 (12.9) 60.5 (14.6) 65.1 (12.2) 66.4 (16.0) 59.3 (16.2) 59.1 (14.5) 62 (13.0)
Female, n (%) 300 (60.7) 188 (67.1) 147 (58.8) 97 (51.0) 101 (64.0) 75 (59.5) 80 (70.8)
FEV1% predicted, mean (SD) 71.6 (24.7) 80.3 (25.9) 79.2 (27.5) 69.3 (25.3) 70.1 (24.9) 64 (26.9) 64.8 (26.2)
BMI, mean (SD) 25.9 (5.2) 27.1 (5.6) 23.7 (4.4) 23.9 (4.3) 24.6 (3.4) 26.2 (5.1) 25.1 (4.9)
Pseudomonas colonisation, n (%) 63 (12.8) 39 (13.9) 54 (21.6) 16 (8.4) 58 (36.5) 13 (10.3) 1 (1%)
Reiff score, mean (SD) 4.4 (3.0) 3.4 (3.0) 5.5 (2.7) 4.5 (1.3) 4.8 (2.5) 2.8 (1.4) 4.7 (2.4)
MRC dyspnoea score, mean (SD) 2.3 (1.1) 2.0 (1.0) 2.0 (1.3) 2.3 (1.2) 2.4 (1.5) 2.5 (1.1) 2.5 (1.4)
Exacerbations/year, mean (SD) 2.1 (2.6) 2.9 (1.3) 1.9 (2.0) 1.9 (2.1) 2.4 (1.5) 3.4 (1.7) 1 (1.25)
LTOT, n (%) 8 (1.6) 9 (3.2) 35 (14.0) 10 (5.3) 26 (16.4) 0 (0) 12 (10.6%)
Prior hospitalisations, n (%) 118 (23.9) 62 (22.1) 34 (13.6) 55 (28.9) 83 (52.2) 75 (59.5) 15 (13.3%)
BSI, mean (SD) 7.3 (4.4) 6.8 (4.5) 7.3 (4.1) 7.6 (4.6) 9.1 (5.4) 9.7 (4.9) 6.0 (3.7)
FACED, mean (SD) 2.1 (1.6) 1.5 (1.5) 2.3 (1.6) 1.9 (0.9) 2.1 (1.8) 1.6 (1.6) 2.3 (1.6)
End points evaluated Mortality
Hospitalisations
Exacerbations
Symptoms
Quality of life
FEV1 decline
Mortality
Hospitalisations
Exacerbations
Mortality
Hospitalisations
Exacerbations
Symptoms
Quality of life
FEV1 decline
Mortality
Hospitalisations
Exacerbations
Mortality
Hospitalisations
Exacerbations
Mortality
Hospitalisations
Exacerbations
Mortality
Hospitalisations
Exacerbations
Follow-up time for mortality, years 4 5 4 5 5 4 5
BMI, body mass index; BSI, Bronchiectasis Severity Index; LTOT, long-term oxygen therapy; MRC, Medical Research Council.
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according to BSI were 0%–14.9% and increased proportionately
across mild, moderate and severe risk groups. Hospitalisation
rates were much more variable for ‘mild’ patients according to
FACED, with rates from 3.3% to 40.7% and, in the Dundee
and Vojvodina cohorts, there was a paradoxically higher per-
centage of hospital admissions in the ‘moderate’ group com-
pared with ‘severe’.
Comparing AUC values for hospitalisations, BSI showed stat-
istically significant superiority in six of seven cohorts when ana-
lysed individually. FACED was only predictive of hospital
admissions in the Galway cohort using the cut-off of 0.7 for
valid discrimination.
Rates of hospital admissions comparing the mild and severe
groups with the moderate group for each severity score are
shown in table 4. Notably, the RR for low-risk patients using
the BSI was numerically lower than FACED in all seven cohorts.
Similarly, RR for hospitalisation in the severe group was numer-
ically higher in five of seven cohorts.
Exacerbations
Exacerbation rates were strongly linked to clinical severity
scores. Using Poisson regression, low-risk patients, determined
by the BSI, had fewer exacerbations in all cohorts and differ-
ences were statistically significant in four out of seven cohorts
(table 5). Severe patients according to the BSI had significantly
more exacerbations than the moderate group across all cohorts.
In contrast, FACED was less consistent for predicting exacerba-
tions. Paradoxically, we observed numerically more exacerba-
tions occurred in the moderate versus severe FACED group in
the Newcastle and Vojvodina cohorts, while ‘mild’ patients had
numerically more exacerbations than moderate patients in the
Monza and Athens cohorts, suggesting that the FACED score
did not reliably and consistently identify patients at high risk of
exacerbations. Differences between mild and moderate FACED
groups were only statistically significant in two out of seven
cohorts (Galway and Vojvodina) and differences between mod-
erate and severe were only statistically significant in four out of
seven cohorts. In the pooled analysis, the differences between
mild and moderate FACED groups were not statistically signifi-
cant, while overall differences between severe and moderate
were significant (table 5).
QoL-B questionnaire
QoL and symptom data were available in two cohorts (744
patients) which were pooled for analysis. Using the QoL-B, stat-
istically significant differences were observed for respiratory
symptoms, physical functioning and role functioning domains
between mild/moderate and moderate/severe groups using the
BSI. All differences were above the MCID (table 6).
There were also significant differences for BSI in the vital-
ity domains across both mild/moderate and moderate/severe
groups but at levels below the MCID. Health perceptions
were not significantly different between mild/moderate groups
but were statistically and clinically different between moderate/
severe groups.
FACED demonstrated less discrimination in terms of QoL-B
domains. There were clinically and statistically significant differ-
ences between the mild/moderate FACED groups for physical
functioning (table 4) but the only other difference exceeding the
MCID was for role-functioning.
Table 2 The overall distribution of patients, number of deaths and number of hospital admissions for severe exacerbations in mild, moderate
and severe groups across the seven cohorts
No. of patients per group Mortality Hospital admissions
Mild, n (%) Moderate, n (%) Severe, n (%) Mild, n (%) Moderate, n (%) Severe, n (%) Mild, n (%) Moderate, n (%) Severe, n (%)
Dundee, Scotland (n=494)
BSI 136 (27.5) 211 (42.7) 147 (29.8) 1 (0.7) 13 (6.2) 28 (19.0) 3 (2.2) 24 (11.4) 75 (51.0)
FACED 303 (61.3) 145 (29.4) 46 (9.3) 12 (4.0) 15 (10.3) 15 (32.6) 44 (14.5) 45 (31.0) 13 (28.3)
Galway, Ireland (n=280)
BSI 109 (38.9) 92 (32.9) 79 (28.2) 8 (7.3) 11 (12.0) 25 (31.6) 2 (1.8) 6 (6.5) 30 (38.0)
FACED 217 (77.5) 53 (18.9) 10 (3.6) 23 (10.6) 19 (35.8) 2 (20.0) 18 (8.3) 15 (28.3) 5 (50.0)
Monza, Italy (n=250)
BSI 67 (26.8) 104 (41.6) 79 (31.6) 0 (0) 3 (2.9) 11 (13.9) 10 (14.9) 27 (25.9) 55 (69.6)
FACED 135 (54.0) 88 (35.2) 27 (10.8) 3 (2.2) 4 (4.5) 7 (25.9) 40 (29.6) 34 (38.6) 18 (66.7)
Leuven, Belgium (n=190)
BSI 51 (26.8) 63 (33.2) 76 (40.0) 2 (3.9) 16 (25.4) 26 (34.2) 6 (11.8) 18 (28.6) 34 (44.7)
FACED 100 (52.6) 65 (34.2) 25 (13.2) 9 (9.0) 19 (29.2) 16 (64.0) 23 (23.0) 22 (33.8) 13 (52.0)
Athens, Greece (n=159)
BSI 36 (22.6) 43 (27.0) 80 (50.3) 0 (0) 0 (0) 9 (11.3) 1 (2.8) 7 (16.3) 27 (33.8)
FACED 104 (65.4) 35 (22.0) 20 (12.6) 0 (0) 4 (11.4) 5 (25.0) 17 (16.3) 9 (25.7) 9 (45.0)
Newcastle, England (n=126)
BSI 21 (16.7) 25 (19.8) 80 (63.5) 0 (0) 1 (4.0) 15 (18.8) 0 (0) 5 (20.0) 52 (65.0)
FACED 91 (72.2) 27 (21.4) 8 (6.3) 6 (6.6) 7 (25.9) 3 (37.5) 37 (40.7) 15 (55.6) 5 (62.5)
Vojvodina, Serbia (n=113)
BSI 41 (36.3) 48 (42.5) 24 (21.2) 0 (0) 12 (25.0) 8 (33.3) 0 (0) 1 (2.1) 12 (50)
FACED 60 (53.1) 44 (38.9) 9 (8.0) 4 (6.7) 13 (29.5) 3 (33.3) 2 (3.3) 10 (22.7) 1 (11.1)
Total (n=1612)
BSI 461 (28.6) 586 (36.4) 565 (35.1) 11 (2.4) 56 (9.5) 122 (21.6) 22 (4.8) 88 (15.0) 285 (49.6)
FACED 1010 (62.7) 457 (28.3) 145 (9.0) 57 (5.6) 81 (17.7) 51 (35.1) 181 (17.9) 150 (32.8) 64 (44.1)
BSI, Bronchiectasis Severity Index.
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Similar data were observed for the SGRQ (figure 1). The dif-
ferences between mild, moderate and severe groups for the BSI
were significant (p<0.0001) with a difference of 11 points
between mild/moderate groups and 12 points between moder-
ate/severe groups, both above the MCID of four points. There
was a 10-point difference between the mild/moderate FACED
groups (p<0.0001) but no difference between moderate/severe
groups, p=0.9. We further validated these findings in the only
other published validation study from the Royal Brompton
Hospital (76 patients).9 In this cohort, there were clear differ-
ences between BSI groups in terms of SGRQ score, with mean
differences of 9 and 11 points comparing mild/moderate with
moderate/severe, respectively (p=0.003). In contrast, there were
no statistically significant differences between FACED groups
and the between-group difference for moderate/severe was
below the MCID, p=0.2 (see online supplementary figure S1).
Symptoms and function
As above, symptom and functional data were only available in
two cohorts (744 patients). Cough severity, evaluated by the
LCQ was different between BSI groups (p<0.0001 by ANOVA)
with mean differences of 1.5 and 1.4 between groups, both
above the stated MCID of 1.3.
There was a significant difference between mild and moderate
FACED groups but this did not reach the MCID (mean differ-
ence 1.1, p=0.005); there was no difference between moderate
and severe groups (mean difference 0.26, p=0.7).
Data for 6 MWD were available for 471 patients. The differ-
ences in 6 MWD between groups for the BSI were 115 m (mild/
moderate) and 83 m (moderate/severe), the latter just failing to
reach the MCID. For FACED, differences were 53 m (mild/mod-
erate) and 21 m (moderate/severe), neither of which is statistic-
ally significant or above the MCID (p=0.2).
There was a weak but statistically significant association
between BSI and annual FEV1 decline (figure 1), driven by a
higher rate of decline in the severe group as there was no differ-
ence between mild and moderate groups (p=0.7). FACED did
not predict lung function decline with the lowest rate of decline
observed in the moderate group.
DISCUSSION
This study is the first multicentre study critically appraising
whether prognostic indices can predict clinically meaningful
outcomes broader than just mortality. If bronchiectasis severity
tools are to be used in clinical practice to guide escalation of
therapy, they need to predict outcomes that are relevant to these
decisions.13 This prospective international observational study
suggests that the BSI is superior to FACED in predicting clinic-
ally important disease-related outcomes, including hospital
admissions, exacerbations, QoL, respiratory symptoms, 6 MWD
and lung function decline in bronchiectasis.
The primary outcome in most intervention trials in bronchiec-
tasis has been exacerbations or QoL; these are also considered
to be the most important triggers for changes in treatment.4–6 13
According to our analysis, the BSI consistently stratified patients
as having low, moderate and high risk of exacerbations and
severe exacerbations requiring hospitalisation, while there were
Table 4 Hospitalisations meta-analysis data. RR of hospitalisation for severe exacerbations during follow-up according to different severity
scores
Cohort Scores RR—mild RR—moderate RR severe
Dundee,
Scotland (n=494)
BSI 0.19 (0.06 to 0.64)* 1.00 (reference) 4.46 (2.82 to 7.07)*
FACED 0.47 (0.31 to 0.71)* 1.00 (reference) 0.91 (0.49 to 1.69)
Galway,
Ireland (n=280)
BSI 0.28 (0.06 to 1.39) 1.00 (reference) 5.82 (2.42 to 14.0)*
FACED 0.29 (0.15 to 0.58)* 1.00 (reference) 1.77 (0.64 to 4.86)
Monza,
Italy (n=250)
BSI 0.50 (0.26 to 0.97)* 1.00 (reference) 4.45 (3.08 to 6.42)*
FACED 0.75 (0.52 to 1.08) 1.00 (reference) 3.69 (2.55 to 5.34)*
Leuven,
Belgium (n=190)
BSI 0.56 (0.29 to 1.30) 1.00 (reference) 1.68 (0.93 to 3.04)
FACED 0.68 (0.38 to 1.22) 1.00 (reference) 1.54 (0.77 to 3.05)
Athens,
Greece (n=159)
BSI 0.17 (0.02 to 1.39) 1.00 (reference) 2.07 (0.90 to 4.76)
FACED 0.64 (0.28 to 1.43) 1.00 (reference) 1.75 (0.70 to 4.41)
Newcastle,
England (n=126)
BSI 0 (no events)* 1.00 (reference) 3.25 (1.30 to 8.14)*
FACED 0.75 (0.40 to 1.41) 1.00 (reference) 1.18 (0.47 to 2.95)
Vojvodina,
Serbia (n=113)
BSI 0 (no events)* 1.00 (reference) 24.5 (3.2 to 188.4)*
FACED 0.15 (0.03 to 0.67)* 1.00 (reference) 0.49 (0.06 to 3.82)
Pooled cohort (n=1612) BSI 0.41 (0.27 to 0.62)* 1.00 (reference) 3.71 (2.95 to 4.66)*
FACED 0.55 (0.41 to 0.75)* 1.00 (reference) 1.58 (0.92 to 2.71)
*Indicates statistical significance at p<0.05. Pooled data were obtained through random effects meta-analysis.
BSI, Bronchiectasis Severity Index; RR, rate ratio.
Table 3 Area under the receiver operator characteristic curve
values for mortality and hospital admissions across seven European
cohorts
Cohort Scores AUC mortality
AUC hospital
admissions
Dundee,
Scotland (n=494)
BSI 0.78 (0.71 to 0.85) 0.84 (0.80 to 0.88)*
FACED 0.76 (0.70 to 0.83) 0.68 (0.63 to 0.73)
Galway,
Ireland (n=280)
BSI 0.73 (0.64 to 0.81) 0.87 (0.80 to 0.93)
FACED 0.71 (0.62 to 0.80) 0.79 (0.73 to 0.86)
Monza,
Italy (n=250)
BSI 0.86 (0.75 to 0.96) 0.79 (0.73 to 0.85)*
FACED 0.77 (0.64 to 0.90) 0.62 (0.55 to 0.70)
Leuven,
Belgium (n=190)
BSI 0.73 (0.65 to 0.81) 0.71 (0.63 to 0.78)
FACED 0.78 (0.70 to 0.86) 0.65 (0.57 to 0.74)
Athens,
Greece (n=159)
BSI 0.93 (0.87 to 0.98) 0.76 (0.67 to 0.84)*
FACED 0.87 (0.80 to 0.94) 0.62 (0.51 to 0.74)
Newcastle,
England (n=126)
BSI 0.82 (0.73 to 0.91)* 0.80 (0.72 to 0.87)*
FACED 0.68 (0.52 to 0.84) 0.56 (0.46 to 0.66)
Vojvodina,
Serbia (n=113)
BSI 0.75 (0.65 to 0.85) 0.97 (0.93 to 1.00)*
FACED 0.74 (0.64 to 0.85) 0.69 (0.58 to 0.81)
Pooled cohort
(n=1612)
BSI 0.76 (0.74 to 0.78) 0.82 (0.78 to 0.84)*
FACED 0.76 (0.74 to 0.78) 0.65 (0.63 to 0.67)
*Indicates p<0.05 compared with FACED. BSI, Bronchiectasis Severity Index.
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lesser differences between FACED risk groups for exacerbations.
Furthermore, FACED had a very poor overall ability to predict
hospitalisations with AUC scores below 0.7 in six of the seven
included cohorts. It is perhaps not surprising that FACED
predicts exacerbations poorly, as although risk factors for
exacerbations in bronchiectasis have not been well defined, data
from COPD show that the strongest predictor of future exacer-
bations is a previous history of exacerbations and anecdotally
the same is true in bronchiectasis.26 27 The BSI incorporates
prior history of mild and severe exacerbations, while the
FACED score does not.
The BSI was also a valid predictor of respiratory symptoms
and physical functioning using the QoL-B, as well as passing val-
idity testing against the SGRQ, the 6 MWD and the LCQ. This
is consistent with multiple studies published over the past
18 months where the BSI has been correlated with the SGRQ,
the COPD assessment test—another measure of symptoms, the
capsaicin cough sensitivity, impulse oscillometry, the 6 MWD
Table 5 RR for exacerbations during follow-up according to different severity scores
Cohort Scores RR—mild RR—moderate RR severe
Dundee,
Scotland (n=494)
BSI 0.66 (0.53 to 0.82)* 1.00 (reference) 2.14 (1.84 to 2.50)*
FACED 0.91 (0.77 to 1.06) 1.00 (reference) 1.44 (1.15 to 1.80)*
Galway,
Ireland (n=280)
BSI 0.70 (0.55 to 0.88) 1.00 (reference) 1.44 (1.16 to 1.78)*
FACED 0.74 (0.59 to 0.92)* 1.00 (reference) 1.25 (0.82 to 1.92)
Monza,
Italy (n=250)
BSI 0.76 (0.59 to 0.99)* 1.00 (reference) 1.38 (1.11 to 1.70)*
FACED 1.06 (0.86 to 1.31) 1.00 (reference) 1.64 (1.24 to 2.17)*
Leuven,
Belgium (n=190)
BSI 0.78 (0.52 to 1.18) 1.00 (reference) 2.08 (1.52 to 2.84)*
FACED 0.86 (0.64 to 1.14) 1.00 (reference) 1.51 (1.05 to 2.16)*
Athens,
Greece (n=159)
BSI 0.67 (0.34 to 1.33) 1.00 (reference) 1.92 (1.21 to 3.04)*
FACED 1.20 (0.73 to 1.96) 1.00 (reference) 2.36 (1.33 to 4.21)*
Newcastle,
England (n=126)
BSI 0.47 (0.32 to 0.71)* 1.00 (reference) 1.29 (1.02 to 1.65)*
FACED 0.81 (0.63 to 1.04) 1.00 (reference) 0.95 (0.64 to 1.41)
Vojvodina,
Serbia (n=113)
BSI 0.14 (0.05 to 0.38)* 1.00 (reference) 2.61 (1.69 to 4.04)*
FACED 0.22 (0.13 to 0.37)* 1.00 (reference) 0.93 (0.49 to 1.77)
Pooled cohort (n=1612) BSI 0.63 (0.52 to 0.78)* 1.00 (reference) 1.73 (1.42 to 2.12)*
FACED 0.78 (0.60 to 1.01) 1.00 (reference) 1.40 (1.16 to 1.68)*
*Indicates statistical significance at p<0.05. Pooled data were obtained through random effects meta-analysis.
BSI, Bronchiectasis Severity Index; RR, rate ratio.
Table 6 QoL-B questionnaire domains
Mean difference
(mild vs moderate) p Value
Mean difference
(moderate vs severe) p Value
Respiratory symptoms (MCID=8)
BSI −10.4 (3.0) 0.0006 −8.8 (2.6) 0.0009
FACED −6.3 (2.5) 0.01 −2.9 (3.4) 0.4
Physical functioning (MCID=10)
BSI −14.8 (4.8) 0.002 −20.7 (3.9) <0.0001
FACED −20.1 (3.7) <0.0001 −4.5 (4.6) 0.3
Vitality (MCID=10)
BSI −7.4 (3.2) 0.02 −6.8 (2.9) 0.02
FACED −7.5 (2.6) 0.005 −2.2 (3.6) 0.5
Role functioning (MCID=8)
BSI −11.1 (4.0) 0.006 −13.9 (3.5) 0.0001
FACED −12.6 (2.2) <0.0001 −8.8 (4.0) 0.03
Health perceptions (MCID=8)
BSI −3.5 (3.5) 0.3 −8.6 (2.9) 0.003
FACED −7.7 (2.7) 0.005 5.2 (4.0) 0.2
Emotional functioning (MCID=7)
BSI −5.0 (3.3) 0.1 −6.1 (3.2) 0.05
FACED −2.2 (2.9) 0.5 −1.2 (4.0) 0.8
Social functioning (MCID=9)
BSI −5.0 (4.0) 0.2 −7.7 (3.7) 0.03
FACED −7.6 (3.2) 0.02 1.6 (4.8) 0.7
Treatment burden (MCID=9)
BSI −6.6 (4.9) 0.2 −5.8 (3.7) 0.1
FACED −3.6 (3.6) 0.3 −2.2 (4.6) 0.6
Values show mean difference with SD for between-group differences. Differences that are statistically significant and above the MCID are shown in bold.
BSI, Bronchiectasis Severity Index; QoL-B, quality of life-bronchiectasis; MCID, minimum clinically important difference.
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and activity measured using accelerometers.28–31 Finally, Dente
et al32 published a significant association between BSI and
sputum neutrophilic inflammation, while no relationship with
FACED was found. In the present analysis, the BSI accurately
categorised different severities of bronchiectasis according to
these parameters, whereas, although sometimes showing trends
towards differences in these parameters, the FACED score did
not pass validity for the majority of QoL-B domains, the
6 MWD or the LCQ.
Our analysis also suggests a relationship between the predictive
ability of the BSI and lung function decline, which again was not
evident with FACED. There have been few studies of lung func-
tion decline in bronchiectasis. In their analysis of 76 patients,
Martínez-García et al found P. aeruginosa colonisation and severe
exacerbations to be the strongest predictors.33 It is perhaps there-
fore not surprising that the BSI predicts lung function decline as
it awards a high proportion of points to P. aeruginosa colonisa-
tion (3 points) and hospitalisation for severe exacerbations (5
points), while FACED awards 1 point to P. aeruginosa colonisa-
tion and does not consider severe exacerbations. Our results are
therefore in keeping with previous studies.
There are clearly advantages and disadvantages to both
scores. The BSI is slightly more complex than the FACED score,
requiring the measurement of 8, rather than 5, clinical para-
meters with a variable weighting that awards different points for
each. Evidence suggests that clinicians may find weighted scores
more difficult to apply leading to an underutilisation in clinical
practice.34 However, in the current era of telemedicine and
online medical calculators that assign a total on inputting the
relevant data in sequential order, this is potentially a concern
of the past.34 35 Although FACED is an acronym that may be
easier for clinicians to remember, the score is subject to the
same limitations, also awarding different weights to different
variables, while having a lower accuracy for the majority of
clinical outcomes.
Our analysis identified several potential limitations of the
FACED score. It failed calibration analysis, suggesting that its pre-
diction performance varies across different healthcare settings and
requires local recalibration before use. We further confirmed this
finding by incorporating the cohort of Ellis et al9 into the analysis
(see online supplementary material), which independently con-
firms the failure of calibration. FACED consistently had a sensiti-
vity of <50% for prediction of mortality and hospitalisations. The
FACED score appears to prioritise specificity over sensitivity. This
is potentially problematic for clinical decision-making, as it is
counterintuitive to say that only a quarter of patients dying of
bronchiectasis or being hospitalised for severe exacerbations have
‘severe’ bronchiectasis. There are some circumstances where a
high specificity, that is, a high confidence that a high-risk patient
will die, is desirable, the most obvious being in assessment of mor-
tality risk in potential lung transplant recipients and the FACED
score appears to be well adapted to this. However, in view of these
limitations and the finding that the ‘severe’ FACED group was not
associated with increased exacerbations or differences in most
Figure 1 Bar graphs showing quality of life, symptoms and lung function decline. For SGRQ and FEV1 decline, bars show mean with SEM.
For Leicester Cough Questionnaire and 6 min walking distance, mean, SD and range are shown. BSI, Bronchiectasis Severity Index, SGRQ, St Georges
Respiratory Questionnaire.
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other morbidity parameters, we suggest that FACED should not be
viewed as a severity assessment tool but rather as a mortality risk
tool and therefore the terms mild, moderate and severe be
replaced with low, intermediate and high risk of mortality when
describing the FACED score.
It is widely accepted that prognostic model development is a
three-stage process, comprising derivation (creating the rule),
validation (applying the rule to new populations of patients to
confirm its accuracy) and impact analysis (applying the rule and
determining if it can improve clinical outcomes for patients).36
Our results suggest the BSI is superior in identifying patients at
low risk of mortality, hospitalisation, exacerbations and morbid-
ity who may benefit from primary care or nurse-led follow-up,
which have the potential to either improve access or reduce
healthcare costs and improve patient satisfaction.37 The BSI is
also more sensitive in identifying patients at high risk of mortal-
ity, hospitalisation and exacerbations who may benefit from
more aggressive treatment early on in their disease course to
reduce associated complications, as well as closer follow-up in
specialist bronchiectasis clinics. Our results do not, however,
prove that implementation of the BSI may improve clinical out-
comes and an impact analysis is now required.
A great strength of the present study is the inclusion of mul-
tiple cohorts across Europe. However, limitations of the study
must be acknowledged. So far these scores have only been eval-
uated in European cohorts with similar demographics. Further
validation would be desirable in populations significantly differ-
ent from the original derivation studies, for example, in the
USA where there is a high prevalence of non-tuberculous myco-
bacteria bronchiectasis or in Asian populations, where the
overall prevalence of bronchiectasis is suspected to be higher
than in Caucasians.38 A large amount of additional data is likely
to be generated by ongoing international registry projects which
incorporate calculation of the BSI.39 40
CONCLUSION
In conclusion, the BSI accurately predicts mortality, hospital
admissions, exacerbations, QoL, respiratory symptoms, 6 MWD
and lung function decline in bronchiectasis, providing a clinic-
ally relevant evaluation of disease severity.
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